Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VV GMCSF Lact

Next Previous
Drug Profile

VV GMCSF Lact

Alternative Names: Double Recombinant Vaccinia Virus VV-GMCSF-Lact; VV-GMCSF-Lact

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Institute of Chemical Biology and Fundamental Medicine; Oncostar; State Research Center of Virology and Biotechnology
  • Class Antineoplastics; Gene therapies; Granulocyte-macrophage colony-stimulating factors; Immunotherapies; Oncolytic viruses; Proteins
  • Mechanism of Action Cell death stimulants; Granulocyte-macrophage colony-stimulating factor expression stimulants; Immunologic cytotoxicity; Lactapin expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Glioblastoma
  • No development reported Breast cancer

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for phase-I development in Breast-cancer(Metastatic disease, Second-line therapy or greater) in Russia (Intratumoural, Injection)
  • 11 May 2022 Phase-I clinical trials in Breast cancer (Recurrent, Refractory metastatic disease) in Russia (Intratumoural) (NCT05376527)
  • 14 Oct 2021 Preclinical trials in Glioblastoma in Russia (Intratumoural) before October 2021

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top